solute carrier family 6 member 11Genealiases: GAT-3 · GAT3 · GAT4
Q-omics provides the consensus-scored SLC6A11 profile across patient tissues and cancer cell-line models. SLC6A11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SLC6A11 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, SLC6A11 RNA expression shows 15,126 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, LUAD, and HNSC as cancer lineages where SLC6A11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A11 survival associations across molecular data types. SLC6A11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A11 RNA expression–survival associations across cancer types. High SLC6A11 expression shows unfavorable associations in UCEC, KIRC, LUSC, LIHC and KIRP, but favorable associations in UVM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SLC6A11 RNA expression.
This table summarizes SLC6A11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A11 shows lower tumor expression in COAD and READ and higher tumor expression in LUAD, HNSC, LIHC and LUSC. The LUAD box plot shows higher SLC6A11 RNA expression in tumor versus normal tissue (log2 FC = +0.955, t-test p < 0.001).
This table shows molecular features associated with SLC6A11 in patient tissues and cancer cell lines. In patient samples, SLC6A11 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
